The MLSC Open Capital Program, one of several Competitive Capital Programs, is designed to provide grants for capital projects that support the life sciences ecosystem in Massachusetts by enabling and supporting life sciences research and development in the Commonwealth. This program is designed to help fund high potential economic development projects that promise to make a significant contribution to the state’s life sciences ecosystem.
All BWH PIs are eligible to apply. As the call from the sponsor states, institutions may submit multiple applications provided that each application is authorized by a senior leader. Dr. Paul Anderson will be signing off on each application, and the BRI will be reviewing applications to confirm that there is no scientific overlap.
Summary: The Damon Runyon Clinical Investigator Award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine.
The applicant must hold an independent assistant professor position or equivalent and must apply within the first five (5) years of their initial full faculty appointment (Cut-off date: July 1, 2015). Adjunct or acting positions are not eligible.
Amount: $1,000,000 (The foundation allows up to $5MM, but typically funds projects in the $1MM range)
Deadline: Dec 09, 2019
Indirect Overhead Rate: The 15% minimum will be covered by the BRI
Internal Applications: Please note, only TWO applications from each BWH department (and TWO applications from each division within the Department of Medicine) will be accepted for this limited submission, invitational funding opportunity. Please seek approval from you department chair or division chief before submitting your application.
These awards support projects that are distinctive and novel in their approach, question the prevailing paradigm, or have the potential to break open new territory in their field. Funding is prioritized for projects that: Focus on important and emerging areas of research; Have the potential to develop breakthrough technologies, instrumentation or methodologies; Are innovative, distinctive and interdisciplinary; Demonstrate a high level of risk due to unconventional approaches, or by challenging the prevailing paradigm; Have the potential for transformative impact, such as the founding of a new field of research, the enabling of observations not previously possible, or the altered perception of a previously intractable problem; Does not focus on clinical or translational research, treatment trials or research for the sole purpose of drug development; Fall outside the mission of public funding agencies; Demonstrate that private philanthropy generally, and the W. M. Keck Foundation in particular, is essential to the project’s success. Click here to read more info and to submit an internal application
Edward Mallinckrodt Foundation for research grant THE GUIDELINES FOR THIS GRANT CHANGED AS OF APRIL 20, 2016. INSTITUTIONS ARE NOW ONLY ALLOWED TO SUBMIT ONE APPLICATION. BWH IS NO LONGER ELIGIBLE TO APPLY FOR THIS GRANT SEPARATELY FROM HMS. THIS GRANT WILL BE PART OF THE HMS FOUNDATION FUND NOMINATION PROCESS GOING FORWARD